News Image

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Provided By GlobeNewswire

Last update: May 14, 2025

- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available in the U.S. -

Read more at globenewswire.com

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (8/28/2025, 8:00:00 PM)

After market: 7 +0.12 (+1.74%)

6.88

-0.02 (-0.29%)



Find more stocks in the Stock Screener

Follow ChartMill for more